Search

Your search keyword '"Mintzer, Jacobo"' showing total 689 results

Search Constraints

Start Over You searched for: Author "Mintzer, Jacobo" Remove constraint Author: "Mintzer, Jacobo"
689 results on '"Mintzer, Jacobo"'

Search Results

2. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease

3. Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease

4. Do Centenarians Get Dementia?

5. Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel Recommendations

7. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data

9. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.

10. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)

12. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

13. A phase 3 trial of IV immunoglobulin for Alzheimer disease

16. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

17. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

18. Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition.

19. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.

20. Neural correlates of episodic memory encoding and resilience to Alzheimer’s Disease in amyloid‐positive cognitively unimpaired individuals

22. Overcoming Recruitment Challenges and Increasing Representation and Diversity of Participation in Early MCI Clinical Trials: The MIND Study Experience

23. Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

24. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial

25. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data

26. Identifying Abnormal Network Alterations Common to Traumatic Brain Injury and Alzheimer’s Disease Patients Using Functional Connectome Data

27. ALUMNI AD Study Design: Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease (S26.006)

28. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)

29. Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment

30. Principal components analysis of agitation outcomes in Alzheimer's disease

32. 18F-florbetapir Positron Emission Tomography–determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery

33. Type 2 diabetes mellitus, brain atrophy, and cognitive decline

34. Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition

35. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm

36. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial

37. Cost Consequence Analysis of ADMET 2

38. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease

40. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial

42. Leukocyte Surface Biomarkers Implicate Deficits of Innate Immunity in Late‐onset Alzheimer’s Disease

43. Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective

44. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease

46. Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer's Disease Study 2

47. Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data

48. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.

Catalog

Books, media, physical & digital resources